MedTrace Logo

Study of AMG 650 in Adult Participants With Advanced Solid Tumors

NCT04293094 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2023-08-24

No results posted yet for this study

Summary

To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Conditions

Interventions

DRUG

AMG 650

AMG 650 administered orally as a tablet.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Volastra Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-11
Primary Completion
2022-10-24
Completion
2023-02-15
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Italy
  • Japan
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04293094 on ClinicalTrials.gov